| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A new agent in the family of antibody–drug conjugates
|
Pivot, Xavier
|
|
2019
|
20 |
8 |
p. 1043-1044
|
artikel
|
| 2 |
Anti-KIR3DL2 therapy in the treatment of Sézary syndrome
|
Quaglino, Pietro
|
|
2019
|
20 |
8 |
p. 1048-1049
|
artikel
|
| 3 |
Are results from clinical trials reliable?
|
The Lancet Oncology,
|
|
2019
|
20 |
8 |
p. 1035
|
artikel
|
| 4 |
Asbestos exposure: the dust cloud lingers
|
The Lancet Oncology,
|
|
2019
|
20 |
8 |
p. 1035
|
artikel
|
| 5 |
Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study
|
Nené, Nuno R
|
|
2019
|
20 |
8 |
p. 1171-1182
|
artikel
|
| 6 |
Cancer and night shift work: what we still do not know and why
|
McConway, Kevin
|
|
2019
|
20 |
8 |
p. 1051-1052
|
artikel
|
| 7 |
Carcinogenicity of night shift work
|
|
|
2019
|
20 |
8 |
p. 1058-1059
|
artikel
|
| 8 |
Clofarabine and cytarabine for acute myeloid leukaemia
|
Stirrups, Robert
|
|
2019
|
20 |
8 |
p. e402
|
artikel
|
| 9 |
Echoes of a failure: what lessons can we learn?
|
Sondak, Vernon K
|
|
2019
|
20 |
8 |
p. 1037-1039
|
artikel
|
| 10 |
Enhancing CAR T-cell therapy through cellular imaging and radiotherapy
|
Minn, Il
|
|
2019
|
20 |
8 |
p. e443-e451
|
artikel
|
| 11 |
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
|
Long, Georgina V
|
|
2019
|
20 |
8 |
p. 1083-1097
|
artikel
|
| 12 |
Improving affordability of new Essential Cancer Medicines
|
't Hoen, Ellen
|
|
2019
|
20 |
8 |
p. 1052-1054
|
artikel
|
| 13 |
Improving selection of individuals into lung cancer screening programmes
|
Berg, Christine D
|
|
2019
|
20 |
8 |
p. 1039-1040
|
artikel
|
| 14 |
Integration of radiotherapy and immunotherapy for treatment of oligometastases
|
Pitroda, Sean P
|
|
2019
|
20 |
8 |
p. e434-e442
|
artikel
|
| 15 |
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
|
Bagot, Martine
|
|
2019
|
20 |
8 |
p. 1160-1170
|
artikel
|
| 16 |
Lapatinib with chemotherapy for gastro-oesophageal cancer
|
Stirrups, Robert
|
|
2019
|
20 |
8 |
p. e400
|
artikel
|
| 17 |
Leukaemia cutis: an unusual localisation in the groin mimicking infection
|
Zang, Peter D
|
|
2019
|
20 |
8 |
p. e464
|
artikel
|
| 18 |
Medical crowdfunding to access CAR T-cell therapy
|
Ho, Linda D
|
|
2019
|
20 |
8 |
p. 1062-1064
|
artikel
|
| 19 |
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial
|
Saadatmand, Sepideh
|
|
2019
|
20 |
8 |
p. 1136-1147
|
artikel
|
| 20 |
Nanoparticle augmentation of radiotherapy in sarcoma
|
Nussbaum, Daniel P
|
|
2019
|
20 |
8 |
p. 1046-1048
|
artikel
|
| 21 |
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
|
Bonvalot, Sylvie
|
|
2019
|
20 |
8 |
p. 1148-1159
|
artikel
|
| 22 |
Neoadjuvant radiotherapy improves hepatectomy survival
|
Gourd, Elizabeth
|
|
2019
|
20 |
8 |
p. e403
|
artikel
|
| 23 |
Of microbes and women: BRCA1, vaginal microbiota, and ovarian cancer
|
Verstraelen, Hans
|
|
2019
|
20 |
8 |
p. 1049-1051
|
artikel
|
| 24 |
Omitting radiotherapy after head and neck cancer surgery
|
Gourd, Elizabeth
|
|
2019
|
20 |
8 |
p. e401
|
artikel
|
| 25 |
Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy
|
Deutsch, Eric
|
|
2019
|
20 |
8 |
p. e452-e463
|
artikel
|
| 26 |
PET or MRI to improve response evaluation in clinical trials?
|
Deroose, Christophe M
|
|
2019
|
20 |
8 |
p. 1060-1062
|
artikel
|
| 27 |
Radioimmunotherapy for the treatment of head and neck cancer
|
Karam, Sana D
|
|
2019
|
20 |
8 |
p. e404-e416
|
artikel
|
| 28 |
Ramucirumab plus pembrolizumab: can we make the maths work?
|
Klempner, Samuel J
|
|
2019
|
20 |
8 |
p. 1041-1043
|
artikel
|
| 29 |
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
|
Herbst, Roy S
|
|
2019
|
20 |
8 |
p. 1109-1123
|
artikel
|
| 30 |
Rational combinations of immunotherapy with radiotherapy in ovarian cancer
|
Herrera, Fernanda G
|
|
2019
|
20 |
8 |
p. e417-e433
|
artikel
|
| 31 |
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
|
Bekaii-Saab, Tanios S
|
|
2019
|
20 |
8 |
p. 1070-1082
|
artikel
|
| 32 |
SNMMI 2019 Annual Meeting
|
Collingridge, David
|
|
2019
|
20 |
8 |
p. 1057
|
artikel
|
| 33 |
Study evidence confirms current clinical practice in refractory metastatic colorectal cancer: the ReDOS trial
|
Hofheinz, Ralf-Dieter
|
|
2019
|
20 |
8 |
p. 1036-1037
|
artikel
|
| 34 |
The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis
|
Del Paggio, Joseph C
|
|
2019
|
20 |
8 |
p. 1065-1069
|
artikel
|
| 35 |
The growing burden of cancer in the Gaza Strip
|
Abdalla, Bowirrat
|
|
2019
|
20 |
8 |
p. 1054-1056
|
artikel
|
| 36 |
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|
Banerji, Udai
|
|
2019
|
20 |
8 |
p. 1124-1135
|
artikel
|
| 37 |
Treatment of tenosynovial giant-cell tumour types
|
Haijun, Tang
|
|
2019
|
20 |
8 |
p. e398
|
artikel
|
| 38 |
Treatment of tenosynovial giant-cell tumour types
|
Nishida, Yoshihiro
|
|
2019
|
20 |
8 |
p. e399
|
artikel
|
| 39 |
Underdiagnosis is the main challenge in breast cancer screening
|
Kuhl, Christiane K
|
|
2019
|
20 |
8 |
p. 1044-1046
|
artikel
|
| 40 |
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study
|
Luo, Yung-Hung
|
|
2019
|
20 |
8 |
p. 1098-1108
|
artikel
|
Tijdschrift beschrijving